Welcome to Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high impact, small molecule products that address critical unmet needs in the treatment of neurodegenerative diseases. The company emphasizes the efficient development and use of capital and strongly protected intellectual property.

Neuraltus has a number of compounds in the pipeline, including a drug to treat Amyotropic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease; a drug that will reduce dyskinesias (jerky involuntary movements) in patients suffering from Parkinson’s disease; and a drug to treat lysosomal storage disorders. Neuraltus is currently focused on conducting and completing Phase 1 and Phase 2 clinical trials for these disorders.